FDA Inspection 1030104 — ImpactLife
The FDA completed an inspection of ImpactLife on October 5, 2017 in Burlington, IA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- October 5, 2017
- Fiscal Year
- 2018
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Burlington, IA (United States)